SITC Guest Society Symposium at the 2013 AAI Annual Meeting
May 4, 2013
9:45 am – 11:45 am
Hawaii Convention Center
Honolulu, Hawaii
There is unequivocal evidence that the host immune response can recognize and shape the outgrowth of spontaneously arising tumors. Although this can lead to tumor elimination, the frequency of cancer in the population suggests that the endogenous response is often incapable of preventing eventual tumor progression. Strategies now exist to modify the innate and adaptive immune systems to enhance the development of therapeutically effective T cell responses. Preclinical and clinical studies addressing the obstacles to efficacy with the goal of establishing responses that can mediate tumor eradication were presented.
9:45 am – 10:09 am | Cancer Immunoediting: Antigens, Mechanisms and Therapeutic Implications Robert D. Schreiber, PhD - Washington University School of Medicine |
10:09 am – 10:33 am | Creating High Avidity T Cells for Targeting Tumors Philip D. Greenberg, MD - University of Washington |
10:33 am – 10:57 am | Innate and Adaptive Immune Regulation within the Tumor Microenvironment Thomas F. Gajewski, MD, PhD - University of Chicago |
10:57 am – 11:21 am | Targeting Tumor Tissues for Improving Immune Responses by Next Generation of Antibody Treatment Yang-Xin Fu, MD, PhD - University of Chicago |
11:21 am – 11:45 am | PD-1/PD-L1 Axis Julie R. Brahmer, MD - John Hopkins |
Thomas F. Gajewski, MD, PhD - University of Chicago
Julie R. Brahmer, MD - John Hopkins
Yang-Xin Fu, MD, PhD - University of Chicago
Thomas F. Gajewski, MD, PhD - University of Chicago
Philip D. Greenberg, MD - University of Washington
Robert D. Schreiber, PhD - Washington University School of Medicine